- New in-vitro studies demonstrate BETADINE® medicines containing Povidone-Iodine (PVP-I) have a rapid virucidal kill rate against MERS coronavirus
- Using antiseptics in infection control can reduce the overuse of antibiotics that leads to resistance
- BETADINE® Gargle and Mouthwash delays the onset of oral mucositis for cancer patients undergoing chemotherapy and radiotherapy, reduces its severity and helps speed up recovery
SINGAPORE, 24 AUGUST 2016 – In-vitro studies presented on 23 August 2016 by Prof. Maren Eggers, at the World Congress of Internal Medicines in Bali, are further proof that BETADINE® medicines containing PVP-I kill viruses associated with the spread of infectious diseases such as SARS, MERS, Ebola, HFMD and influenza.
An in-vitro study on 4% PVP-I (BETADINE® Skin Cleanser), 7.5% PVP-I (BETADINE® Surgical Scrub), 1% PVP-I (BETADINE® Gargle and Mouthwash), 10% PVPI (BETADINE® Antiseptic Solution) demonstrated their virucidal activity against MERS coronavirus and the Modified Vaccinia Ankara (MVA). MVA is the model virus in Europe for the claim that ‘hygienic hand rub and hand wash are virucidal active against enveloped viruses’ which are common causes of emerging and re-emerging infectious diseases Ebola, Influenza and Coronaviruses are also enveloped viruses.4
The study was conducted based on the latest European Union test standard EN14476:2014 for antiviral enveloped virus testing (similar to that for Ebola). The three PVP-I medicines were proven to have a rapid virucidal kill rate against viruses causing MERs, SARs, Influenza of ≥99.99% within only 15 seconds of exposure.4
“This study not only highlights exciting new findings about the virucidal properties of BETADINE®, it also reminds us that proper hygiene is required to protect the health of both healthcare professionals and the public in the global fight against diseases,” said Prof. Maren Eggers, Head of Experimental Virology and Department of Disinfectant Testing at the Laboratory Prof. G Enders, MVZ Stuttgart.
The World Health Organisation has issued guidelines that highlight the importance of hygiene and regular hand washing in disease prevention and infection control3.
Dr. Li Kie Chen, an expert on infectious and tropical diseases from the Faculty of Medicine University of Indonesia – Cipto Mangunkusumo Hospital said, “Establishing a solid understanding of the use of antibiotics and antiseptics is key to reducing the overuse of antibiotics that leads to resistance.”
Resistant microorganisms are able to withstand attack by antimicrobial drugs, including antibiotics, antifungals, antivirals, and antimalarials. The misuse of antimicrobial drugs accelerates the emergence of drug-resistant strains and infections caused by this often fail to respond to treatment, resulting in prolonged illness and greater risk of death.2
Dr. Jeeve Kanagalingam, Director of the ENT practice at Mount Elizabeth Novena Specialist Center in Singapore highlighted the importance of effective treatment for the relief of oral mucositis (OM) 1 in cancer patients undergoing chemotherapy and radiotherapy.
In severe cases of OM cancer therapy can be disrupted and discontinued, which can directly affect patient survivorship.5
“PVP-I has been a trusted antiseptic for years. It reduces severity, delays onset and leads to faster recovery from OM. This avoids disruption to cancer treatment. Better OM management can improve cancer patients’ quality of life,” said Dr. Kanagalingam added.
1. J.Kanagalingam, et al. Int J Clin Practice doi: 10.1111/ijcp.12707 http://onlinelibrary.wiley.com/doi/10.1111/ijcp.12707/epdf
2. http://www.who.int/mediacentre/factsheets/fs194/en/ (Accesed on August. 15, 2016)
3. Eggers M, et al. Infect Dis Ther. 2015 Dec;4(4):491-501. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675768/pdf/40121_2015_Article_91.pdf
4. http://www.cancer.gov/about-cancer/treatment/side-effects/mouth-throat/oral-complications-hp-pdq#section/_338 (Accesed on August. 15, 2016)
5. http://www.cancer.gov/about-cancer/treatment/side-effects/mouth-throat/oral-complications-hp-pdq (Accesed on August. 15, 2016)
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
For more information please visit: www.mundipharma.com.sg
The BETADINE® range of medicines containing Povidone-Iodine is trusted by hospitals around the world for over 60 years to prevent and treat infections. A trusted brand among consumers at home to treat small wounds and grazes, sore throats, feminine infections and to stop minor problems from escalating into big issues. In-vitro studies show that BETADINE® medicines containing Povidone-Iodine kill a broad range of bacteria, viruses and fungi including antibiotic-resistant strains that cause infections. BETADINE® has four main categories of products in Wound Care, Feminine Care, Throat / Oral Care and Infectious Diseases to meet the varying needs of our customers.
®: BETADINE is a registered trademark of Mundipharma
Registered indications differ country to country hence please check with a local Mundipharma office for more information on the local approved prescribing information.Tags: press releases